# A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

> **NCT07305974** · PHASE2 · RECRUITING · sponsor: **Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- IgA Nephropathy (IgAN)

## Interventions

- **DRUG:** RG002C0106
- **DRUG:** placebo subcutaneous administration

## Key facts

- **NCT ID:** NCT07305974
- **Lead sponsor:** Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07305974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07305974, "A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07305974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*